Literature DB >> 34039038

Perfusion and permeability as diagnostic biomarkers of cavernous angioma with symptomatic hemorrhage.

Je Yeong Sone1, Yan Li1,2, Nicholas Hobson1, Sharbel G Romanos1, Abhinav Srinath1, Seán B Lyne1, Abdallah Shkoukani1, Julián Carrión-Penagos1, Agnieszka Stadnik1, Kristina Piedad1, Rhonda Lightle1, Thomas Moore1, Ying Li1, Dehua Bi1,3, Robert Shenkar1, Timothy Carroll4, Yuan Ji3, Romuald Girard1, Issam A Awad1.   

Abstract

Cavernous angiomas with symptomatic hemorrhage (CASH) have a high risk of rebleeding, and hence an accurate diagnosis is needed. With blood flow and vascular leak as established mechanisms, we analyzed perfusion and permeability derivations of dynamic contrast-enhanced quantitative perfusion (DCEQP) MRI in 745 lesions of 205 consecutive patients. Thirteen respective derivations of lesional perfusion and permeability were compared between lesions that bled within a year prior to imaging (N = 86), versus non-CASH (N = 659) using machine learning and univariate analyses. Based on logistic regression and minimizing the Bayesian information criterion (BIC), the best diagnostic biomarker of CASH within the prior year included brainstem lesion location, sporadic genotype, perfusion skewness, and high-perfusion cluster area (BIC = 414.9, sensitivity = 74%, specificity = 87%). Adding a diagnostic plasma protein biomarker enhanced sensitivity to 100% and specificity to 85%. A slightly modified derivation achieved similar accuracy (BIC = 321.6, sensitivity = 80%, specificity = 82%) in the cohort where CASH occurred 3-12 months prior to imaging after signs of hemorrhage would have disappeared on conventional MRI sequences. Adding the same plasma biomarker enhanced sensitivity to 100% and specificity to 87%. Lesional blood flow on DCEQP may distinguish CASH after hemorrhagic signs on conventional MRI have disappeared and are enhanced in combination with a plasma biomarker.

Entities:  

Keywords:  Cavernous angioma with symptomatic hemorrhage; MR perfusion; MR permeability; biomarkers; machine learning

Mesh:

Substances:

Year:  2021        PMID: 34039038      PMCID: PMC8756480          DOI: 10.1177/0271678X211020587

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.960


  45 in total

1.  Measurement of brain perfusion, blood volume, and blood-brain barrier permeability, using dynamic contrast-enhanced T(1)-weighted MRI at 3 tesla.

Authors:  Henrik B W Larsson; Frédéric Courivaud; Egill Rostrup; Adam E Hansen
Journal:  Magn Reson Med       Date:  2009-11       Impact factor: 4.668

2.  Cerebral cavernous malformation protein CCM1 inhibits sprouting angiogenesis by activating DELTA-NOTCH signaling.

Authors:  Joycelyn Wüstehube; Arne Bartol; Sven S Liebler; René Brütsch; Yuan Zhu; Ute Felbor; Ulrich Sure; Hellmut G Augustin; Andreas Fischer
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-24       Impact factor: 11.205

3.  Atorvastatin Treatment of Cavernous Angiomas with Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC) Trial.

Authors:  Sean P Polster; Agnieszka Stadnik; Amy L Akers; Ying Cao; Gregory A Christoforidis; Maged D Fam; Kelly D Flemming; Romuald Girard; Nicholas Hobson; James I Koenig; Janne Koskimäki; Karen Lane; James K Liao; Cornelia Lee; Seán B Lyne; Nichol McBee; Leslie Morrison; Kristina Piedad; Robert Shenkar; Matthew Sorrentino; Richard E Thompson; Kevin J Whitehead; Hussein A Zeineddine; Daniel F Hanley; Issam A Awad
Journal:  Neurosurgery       Date:  2019-12-01       Impact factor: 4.654

4.  Vascular permeability in cerebral cavernous malformations.

Authors:  Abdul G Mikati; Omaditya Khanna; Lingjiao Zhang; Romuald Girard; Robert Shenkar; Xiaodong Guo; Akash Shah; Henrik B W Larsson; Huan Tan; Luying Li; Matthew S Wishnoff; Changbin Shi; Gregory A Christoforidis; Issam A Awad
Journal:  J Cereb Blood Flow Metab       Date:  2015-05-13       Impact factor: 6.200

5.  Phantom validation of quantitative susceptibility and dynamic contrast-enhanced permeability MR sequences across instruments and sites.

Authors:  Nicholas Hobson; Sean P Polster; Ying Cao; Kelly Flemming; Yunhong Shu; John Huston; Chandra Y Gerrard; Reed Selwyn; Marc Mabray; Atif Zafar; Romuald Girard; Julián Carrión-Penagos; Yu Fen Chen; Todd Parrish; Xiaohong Joe Zhou; James I Koenig; Robert Shenkar; Agnieszka Stadnik; Janne Koskimäki; Alexey Dimov; Dallas Turley; Timothy Carroll; Issam A Awad
Journal:  J Magn Reson Imaging       Date:  2019-09-12       Impact factor: 4.813

6.  Cerebral cavernous malformations proteins inhibit Rho kinase to stabilize vascular integrity.

Authors:  Rebecca A Stockton; Robert Shenkar; Issam A Awad; Mark H Ginsberg
Journal:  J Exp Med       Date:  2010-03-22       Impact factor: 14.307

Review 7.  Recent insights into cerebral cavernous malformations: the molecular genetics of CCM.

Authors:  Florence Riant; Francoise Bergametti; Xavier Ayrignac; Gwenola Boulday; Elisabeth Tournier-Lasserve
Journal:  FEBS J       Date:  2010-01-22       Impact factor: 5.542

8.  Mutations in a gene encoding a novel protein containing a phosphotyrosine-binding domain cause type 2 cerebral cavernous malformations.

Authors:  Christina L Liquori; Michel J Berg; Adrian M Siegel; Elizabeth Huang; Jon S Zawistowski; T'Prien Stoffer; Dominique Verlaan; Fiyinfolu Balogun; Lori Hughes; Tracey P Leedom; Nicholas W Plummer; Milena Cannella; Vittorio Maglione; Ferdinando Squitieri; Eric W Johnson; Guy A Rouleau; Louis Ptacek; Douglas A Marchuk
Journal:  Am J Hum Genet       Date:  2003-11-17       Impact factor: 11.025

9.  Endothelial TLR4 and the microbiome drive cerebral cavernous malformations.

Authors:  Alan T Tang; Jaesung P Choi; Jonathan J Kotzin; Yiqing Yang; Courtney C Hong; Nicholas Hobson; Romuald Girard; Hussein A Zeineddine; Rhonda Lightle; Thomas Moore; Ying Cao; Robert Shenkar; Mei Chen; Patricia Mericko; Jisheng Yang; Li Li; Ceylan Tanes; Dmytro Kobuley; Urmo Võsa; Kevin J Whitehead; Dean Y Li; Lude Franke; Blaine Hart; Markus Schwaninger; Jorge Henao-Mejia; Leslie Morrison; Helen Kim; Issam A Awad; Xiangjian Zheng; Mark L Kahn
Journal:  Nature       Date:  2017-05-10       Impact factor: 49.962

10.  Cerebral cavernous malformations arise from endothelial gain of MEKK3-KLF2/4 signalling.

Authors:  Zinan Zhou; Alan T Tang; Weng-Yew Wong; Sharika Bamezai; Lauren M Goddard; Robert Shenkar; Su Zhou; Jisheng Yang; Alexander C Wright; Matthew Foley; J Simon C Arthur; Kevin J Whitehead; Issam A Awad; Dean Y Li; Xiangjian Zheng; Mark L Kahn
Journal:  Nature       Date:  2016-03-30       Impact factor: 49.962

View more
  2 in total

1.  Perfusion and Permeability MRI Predicts Future Cavernous Angioma Hemorrhage and Growth.

Authors:  Je Yeong Sone; Nicholas Hobson; Abhinav Srinath; Sharbel G Romanos; Ying Li; Julián Carrión-Penagos; Abdallah Shkoukani; Agnieszka Stadnik; Kristina Piedad; Rhonda Lightle; Thomas Moore; Dorothy DeBiasse; Dehua Bi; Robert Shenkar; Timothy Carroll; Yuan Ji; Romuald Girard; Issam A Awad
Journal:  J Magn Reson Imaging       Date:  2021-09-24       Impact factor: 5.119

2.  COVID-19 in a Hemorrhagic Neurovascular Disease, Cerebral Cavernous Malformation.

Authors:  Abdallah Shkoukani; Abhinav Srinath; Agnieszka Stadnik; Romuald Girard; Robert Shenkar; Adrienne Sheline; Kristen Dahlem; Cornelia Lee; Kelly Flemming; Issam A Awad
Journal:  J Stroke Cerebrovasc Dis       Date:  2021-09-08       Impact factor: 2.136

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.